The Management Board of CytoTools AG has started the phase III clinical study for the approval of its wound healing product DermaPro in Europe as announced. After the study design has already been approved by the European Medicines Agency (EMA), the study is expected to begin in the respective countries following approval by the relevant state authorities, such as the Federal Institute for Drugs and Medical Devices (BfArM). The study design, which has been agreed with the EMA, plans to test the active ingredient DPOCL contained in DermaPro for complete wound closure in up to 400 test persons in a treatment period of no more than 12 weeks.